Floatz logo

18f-op-801

Alzheimer Disease (AD)

Ashvattha Therapeutics, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

316 Active assets in the Alzheimer Disease (AD) cohort.

Asset / SponsorPhaseRating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 4BBB
Cipralex
NYU Langone Health
Phase 4BBB
Namenda
Carnot Laboratories
Phase 4BBB
PROPOFOL
Nyree Penn
Phase 4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Anhui Provincial Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

18f-op-801 is also rated in:

multiple sclerosisDormant
CC
Indicative ·
47 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative ·
45 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →